Closing the Earnings Gap
Executive Summary
According to Boston Consulting Group, patent expirations and market pressures mean that the existing pipeline of drugs will generate an average of only 5.5% annual earnings growth--less than half the 13% necessary to meet shareholder expectations. To grow earnings at the required rate, companies need to pursue a combination of new product strategies, improving margins through cost reductions and growing existing products.